Verge Genomics, which is developing treatments for ALS and Parkinson's, has raised series A funding from backers including WuXi AppTec.

US-based genomic drug developer Verge Genomics secured $32m in series A funding on Monday, from investors including pharmaceutical firm WuXi AppTec, which participated through its corporate venturing fund.

Venture capital firm DFJ led the round, which also featured the amyotrophic lateral sclerosis (ALS)-focused ALS Investment Fund, venture capital firm Agent Capital and VC fund OS Fund. DFJ partner Emily Melton will join the company’s board of directors.

Founded in 2015, Verge has created a drug development platform that utilises experimental…